101080-17-5

Usage

Uses

Used in Pharmaceutical Industry:
1H-Pyrazole-4-carboxamide,5-amino-1,3-dimethyl-(9CI) is used as a potential drug candidate for the development of new medications due to its distinctive molecular structure and possible biological properties. Its exploration in this field requires further research and studies to understand its properties and potential therapeutic applications.
Further research and studies are essential to delve into the specific applications of 1H-Pyrazole-4-carboxamide,5-amino-1,3-dimethyl-(9CI) in the pharmaceutical industry, such as its potential role in the treatment of various diseases or conditions. 1H-Pyrazole-4-carboxamide,5-amino-1,3-dimethyl-(9CI)'s unique structure and potential biological activities suggest that it may offer novel therapeutic options, but its exact uses and mechanisms of action need to be determined through rigorous scientific investigation.

Upstream product

• 5417-82-3 (1-ethoxyethylidene)malononitrile 
• 54820-92-7 1,3-dimethyl-5-amino-1H-pyrazole-4-carbonitrile 

Downstream Products

• 1072895-79-4 1,3-dimethyl-1,7-dihydro-pyrazolo[3,4-d]pyrimidine-4,6-dione 
• 87412-89-3 4-chloro-1,3-dimethylpyrazolo<3,4-d>pyrimidine 
• 168464-25-3 1-Ethyl-3-methyl-6-(2-propoxy 5-nitrophenyl)-1,5-dihydro-pyrazolo [3,4-d]pyrimidin-4-one 
• 168464-31-1 1-Ethyl-3-methyl-6-(2-propoxy-5-aminophenyl)-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one 

Relevant academic research and scientific papers

PYRAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE

Compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. [Fomula I]

Synthesis and cyclic GMP phosphodiesterase inhibitory activity of a series of 6-phenylpyrazolo[3,4-d]pyrimidones

A series of 6-phenylpyrazolo[3,4-d]pyrimidones is described which are specific inhibitors of cGMP specific (type V) phosphodiesterase. Enzymatic and cellular activity as well as in vivo oral antihypertensive activity are evaluated. A n-propoxy group at the 2-position of the phenyl ring is necessary for activity. A series of products substituted at the 5-position in addition to the 2-n-propoxy was prepared and evaluated. This position can accommodate many unrelated groups. Amino derivatives were very potent but lacked metabolic stability. Substitution by carbon-linked small heterocycles provided both high levels of activity and stability. Cellular activity very often correlated with in vivo activity. Among the compounds, 1,3-dimethyl-6- (2-propoxy-5-methanesulfonamidophenyl)-1,5-dihydropyrazolo[3,4-d]pyrimidin- 4-one (38) and 1-ethyl-3-methyl-6-(2-propoxy-5-(4-methylthiazol-2-yl)phenyl)- 1,5-dihydropyrazolo[3,4-d]pyrimidin-4-one (59) displayed outstanding in vivo activities at 5 mg/kg/os and good metabolic stabilities.